Skip to main navigation Skip to search Skip to main content

Bortezomib, adriamycin dexamethasone (PAD) combination therapies or patients with relapsed or refractory myeloma previously treated with VAD or VAD like therapy.

  • Michael O'Dwyer

Research output: Other contribution (Published)Other contribution

Original languageEnglish (Ireland)
Media of outputMeeting
Volume108
Publication statusPublished - 1 Nov 2006

Cite this